MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Stock
NASDAQ · MLTX
12.55
Fundamentals
Market cap
$1.05B
Price / Earnings ratio
-4.0x
Price / Sales ratio
N/A
Price / Book ratio
2.5x
Return on assets
-0.6%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About MoonLake Immunotherapeutics Class A Ordinary Shares
No description available.
SectorHealthcare
IndustryBiotechnology
Employees130
CEODr. Jorge Santos da Silva Ph.D.
IPO DateOct 20, 2020
HeadquartersZug, Switzerland
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jorge Santos da Silva Ph.D. | Co-Founder, Interim Chair of the Board & CEO | 1977 |
| Dr. Kristian Reich M.D., Ph.D. | Co-Founder & Chief Scientific Officer | 1966 |
| Mr. Matthias Bodenstedt | Chief Financial Officer | 1988 |
| Mr. Oliver Daltrop Ph.D. | Chief Technical Officer | — |
| Ms. Carla Bretes | Director of Investor Relations & External Communications | — |
| Mr. Nicolas Mosimann Ph.D. | General Counsel | — |
| Joana Cortez | Associate Vice-President of Legal & Compliance | — |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing | — |
| Luciana Marques | Associate Vice-President of HR, People and Culture | — |
| Ms. Nuala Brennan | Chief Clinical Development Officer | — |
Fundamentals
Valuation
Market cap$1.05B
Price-to-sales ratioN/A
Price-to-book value2.46
Price-earnings ratio-4.00
Return on Equity-86.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-3.84
Income Statement
Average volume1,442,418
EBITDA$-245.81M
1 year high (52w)$62.75
1 year low (52w)$5.95
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



